Find the latest Theratechnologies Inc. B2Gold Declares Fourth Quarter 2023 Dividend. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. MONTREAL, Oct. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 25. 5000 0. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. (“Theratechnologies”) with the Securities and Exchange Commission (the. We also use them to share. Biopharmaceutical company Theratechnologies Inc. Senior Director, Investor Relations. . TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. This suggests a possible upside of 2,471. This news release constitutes a. 89 $2. Their average twelve-month price target is $36. 1-514-336-7800. Competitors: Unknown. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Cookies are used to offer you a better browsing experience and to analyze our traffic. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The reported ($0. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. Market Cap. We also use them to share usage information with our partners. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. 4. Patient assistance: 833-238-4372. Stockhouse. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. $109. By continuing to use our service, you agree to our use of cookies. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. Cookies are used to offer you a better browsing experience and to analyze our traffic. Trogarzo® and. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. TH | September 5, 2023. . Betteryear2. was a. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. Investor Relations. T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The business had revenue of $27. com uses cookies on this site. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. By continuing to use our service, you agree to our use of cookies. (THTX) NasdaqCM - NasdaqCM Real Time Price. com uses cookies on this site. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Sept. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Heures de négociation. 00%. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. It's a different kind of fat that may require a different type of treatment. RESSOURCES. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. com uses cookies on this site. Stockhouse. com uses cookies on this site. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. $103. 4% from the stock's current price. P. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. 08 (+6. com. THERATECHNOLOGIES INC. Theratechnologies's earnings have been declining at an average annual rate of -35. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. Investor inquiries: Elif McDonald. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. This news release constitutes a “designated news release” for the purposes of the. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. 1-438. Stockhouse. com uses cookies on this site. Stockhouse. Theratechnologies Inc. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. MONTREAL, Jan. 06 million, an increase of 14. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. Stockhouse. Theratechnologies Announces 1-for-4 Reverse Stock Split. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Theratechnologies layoffs. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. NEW YORK, Dec. Stockhouse. 617-356-1009. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. L. Q4 2022 consolidated revenue growth of 14. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. (THTX) stock. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. TH 48% v4,15M c1. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. L. We also use them to share usage information with our partners. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. T. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. 86%. 8 million. MONTREAL, Oct. 23) earnings per share over the last year ( ($1. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (882) posted 3 minutes ago. FY2023 revenue guidance range set between $90 million and $95 million. By continuing to use our service, you agree to our use of cookies. , alpha and beta) for all equities such as Theratechnologies. Theratechnologies Appoints New Board Member. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. m. By continuing to use our service, you agree to our use of cookies. Cookies are used to. There are 102 news items for this page. Shares of Theratechnologies are up 4. View real-time stock prices and stock quotes for a full financial overview. THTX | Complete Theratechnologies Inc. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. T. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. com uses cookies on this site. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. Theratechnologies Inc. 26 +15. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Their THTX share price targets range from $36. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 4% annually. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. We also use them to share usage. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. 2. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. By continuing to use our service, you agree to our use of cookies. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. 00, suggesting a possible upside of. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. Montréal, Québec, Canada . MONTREAL, Aug. The firm offers its product under the brand name of. : 001-35203 Mr. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 23 to a day high of $1. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Cookies are used to offer you a better browsing experience and to analyze our traffic. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. Story. com uses cookies on this site. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. VANCOUVER, British Columbia, Nov. “This is yet another major achievement for our oncology program. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. MONTREAL, Oct. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. C. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 9% more than in 2021. Stockhouse. 35 as of 10:41 a. - Q3 2022 North American Revenue Growth of 19%. Investor Relations. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal year 2022. This news release constitutes a “designated news release” for the purposes of the Company’s. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. S. FAQ – Émetteurs inscrits NOUVEAU. stock news by MarketWatch. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 63. Statut du système de négociation. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. The company was. The price has fallen in 5 of the last 10 days. 06 million, an increase of. In 2022, THTX's revenue was 80. MONTREAL, Oct. Stockhouse. 1. $30. Image source: The Motley Fool. Focused on small-cap companies and sectors. Cookies are used to offer you a better browsing experience and to analyze our traffic. 40%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. First Quarter Fiscal 2022 Financial Results. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. stock news by MarketWatch. Theratechnologies has generated ($1. Cookies are used to offer you a better browsing experience and to analyze our traffic. - 2023 Q3 positive adjusted EBITDA to be. 00 in the next twelve months. We also use them to share usage information with our partners. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. 3. We also use them to share usage. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com 10/16/2023. FY2023 revenue guidance range set between $90 million and $95 million. Cookies are used to offer you a better browsing experience and to analyze our traffic. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. In the United States, Trogarzo ® (ibalizumab. 20% from a day low at $1. Losses were -47. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. 02%. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies, Inc. 5%. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Apr 14, 2020, 8:30 a. 1-514-336-7800. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 514-336-7800. Last Reviewed: February 24, 2023. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. com uses cookies on this site. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. MONTREAL, Jan. Cookies are used to offer you a better browsing experience and to analyze our. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . One reason for that is that this tier does not include penny stocks. 72%. . com. 8. Theratechnologies had a negative net margin of 36. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. Theratechnologies inc. Watch list NEW Set a price target alert After Hours Last. Company Type For Profit. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. Phone Number (514) 336-7800. Investor Relations. 67, which is an increase of 1,144. For investor inquiries: Leah Gibson. Clinical-stage pharmaceutical company Theralase Technologies Inc. Northwest also announces an update on its. We also use them to share usage information with our partners. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. We also use them to share. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. Cookies are used to offer you a better browsing experience and to analyze our traffic. T. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. If you have HIV, it's important to know the difference. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. 75. T. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. NCU. By continuing to use our service, you agree to our use of cookies. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. acts as investment manager. The company reported ($0. The company had revenue of $20. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. 25 to $1. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Phone Number 15143319691. TH1902 combines Theratechnologies’ proprietary peptide to. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. - Q3 2022 Consolidated Revenue Growth of 17% to $20. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . MONTREAL, Feb. . (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. . Register for your free account today at data. Theratechnologies Inc.